RESEARCHERS have discovered a new way to treat a common type of liver cancer.
The Centenary Institute-led study revealed, HERE, that an encouraging treatment utilises a new drug called Blockmir CD5-2, in combination with a drug called programmed cell death protein 1 antibody.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Sep 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Sep 23
